Dannex Ayrton Starwin Plc

Equities

DASPHARMA

GHEDASP58306

End-of-day quote Ghana S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.38 ^GHS	0.00%		0.00%	-5.00%

2021	Dannex Ayrton Starwin Plc Announces Unaudited Earnings Results for the Period Ended March 31, 2021	CI
2021	Dannex Ayrton Starwin Plc Reports Unaudited Earnings Results for the Year Ended December 31, 2020	CI

Dannex Ayrton Starwin : PR. No 293/2023 DANNEX AYRTON STARWIN PLC (DASPHARMA)- ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022

August 01, 2023 at 02:30 pm EDT

PR 293 DANNEX AYRTON STARWIN PLC ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022(1)

PR 293 DANNEX AYRTON STARWIN PLC ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022(2)

Attachments

Original Link
Original Document
Permalink

Disclaimer

Dannex Ayrton Starwin plc published this content on 31 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 August 2023 18:29:08 UTC.

Latest news about Dannex Ayrton Starwin Plc

Dannex Ayrton Starwin Plc Announces Unaudited Earnings Results for the Period Ended March 31, 2021	21-05-01	CI
Dannex Ayrton Starwin Plc Reports Unaudited Earnings Results for the Year Ended December 31, 2020	21-02-03	CI
Dannex Limited completed the acquisition of remaining unknown minority stake in Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd.	20-01-07	CI
Dannex Limited agreed to acquire remaining unknown minority stake in Starwin Products Company Limited/Ayrton Drug Manufacturing Ltd.	18-12-18	CI
Dannex Limited completed the acquisition of 53.47% stake in Ayrton Drugs Manufacturing Company Ltd. from Adcock Ingram Holdings Limited.	16-12-01	CI
Dannex Limited entered into a sale of shares agreement to acquire 53.47% stake in Ayrton Drugs Manufacturing Company Ltd. from Adcock Ingram Holdings Limited.	16-08-25	CI

Chart Dannex Ayrton Starwin Plc

Duration

Period

More charts

Company Profile

Dannex Ayrton Starwin Plc specialises in the manufacture and distribution of pharmaceutical products.

Sector

More about the company